Gynecologic Oncology | Specialty

Farletuzumab/Chemo Fails to Improve PFS in Platinum-Sensitive, Recurrent Ovarian Cancer With Low CA-125

March 25th 2021

The addition of farletuzumab to carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin did not demonstrate superiority over placebo plus chemotherapy in patients with platinum-sensitive recurrent ovarian cancer who are in their first relapse and have low cancer antigen-125 levels.

Mirvetuximab Soravtansine Monotherapy Under Exploration in Platinum-Resistant FRα+ Ovarian Cancer

March 25th 2021

The exploration of mirvetuximab soravtansine as a potentially efficacious treatment in patients with advanced, high-grade, platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor–alpha expression continues with the ongoing, single-arm, phase 3 SORAYA trial.

Dostarlimab Delivers Durable Responses in dMMR/MMRp Endometrial Cancer

March 24th 2021

Dostarlimab demonstrated durable antitumor activity in patients with mismatch repair deficient and MMR proficient endometrial cancer, regardless of investigator assessment or blinded independent central review and immune-related RECIST or RECIST v1.1 criteria.

AVB-500/Paclitaxel Demonstrates Clinical Benefit in Platinum-Resistant Ovarian Cancer

March 23rd 2021

The GAS6/AXL inhibitor AVB-500, when combined with paclitaxel, elicited clinical benefit with favorable tolerability in patients with platinum-resistant ovarian cancer, according to data from a phase 1b study.

PARP Inhibition Presses Forward With the Possibility of Retreatment and Combo Approaches in Ovarian Cancer

March 23rd 2021

Jing-Yi Chern, MD, ScM, discusses the role of maintenance PARP inhibition in patients with recurrent platinum-sensitive ovarian cancer, as well as remaining questions regarding the utility of PARP inhibitors in this setting.

Dr. Hamilton on the Evaluation of Lucitanib/Nivolumab in Gynecologic Cancers

March 22nd 2021

Erika P. Hamilton, MD, discusses the phase 2 LIO-1 trial evaluation of lucitanib and nivolumab across different gynecologic cancer subtypes.

Olaparib Maintains Acceptable Safety Profile in Platinum-Sensitive, Relapsed Ovarian Cancer

March 22nd 2021

Olaparib, when used in patients with platinum-sensitive relapsed ovarian cancer who had a known BRCA mutation and homologous recombination deficiency status, demonstrated adverse effects that proved to be consistent with the established safety profile of the PARP inhibitor.

Maintenance Niraparib Maintains PFS Improvement in gBRCA+/- Ovarian Cancer

March 22nd 2021

Maintenance niraparib demonstrated clinical benefit that persisted beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations.  

Olaparib/Cediranib Fails to Significantly Improve PFS Over Cediranib Alone in Advanced Endometrial Cancer

March 22nd 2021

Although the combination of olaparib and cediranib showcased modest efficacy over cediranib alone in patients with recurrent, metastatic or persistent endometrial cancer, the difference was not statistically significant.

Maintenance Olaparib Maintains PFS Benefit at 5 Years in Ovarian Cancer

March 21st 2021

Maintenance olaparib showcased progression-free survival benefit in almost half of the patients with ovarian cancer vs 21% of those who received placebo, including consistent benefit in high- and low-risk patients.